FDA Approval for APONVIE issued to HERON THERAPS INC
Unavailable
Unavailable
Date | Price Target | Rating | Analyst |
---|---|---|---|
6/13/2024 | $7.00 | Buy | Rodman & Renshaw |
4/23/2024 | $6.00 | Overweight | CapitalOne |
3/13/2024 | $4.00 → $5.00 | Buy | Needham |
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
Rodman & Renshaw initiated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $7.00
CapitalOne initiated coverage of Heron Therapeutics with a rating of Overweight and set a new price target of $6.00
Needham reiterated coverage of Heron Therapeutics with a rating of Buy and set a new price target of $5.00 from $4.00 previously
SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth. "Now is the right time to add substantial BD and M&A experience to the management team at Heron, and I welcome Brett to
Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act")SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent corporate updates. "We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success. We are improvi
SAN DIEGO, July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator with the passcode 1737564 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast
Submission status for HERON THERAPS INC's drug APONVIE (SUPPL-3) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 216457, Application Classification: Labeling
Submission status for HERON THERAPS INC's drug CINVANTI (SUPPL-15) with active ingredient APREPITANT has changed to 'Approval' on 03/05/2024. Application Category: NDA, Application Number: 209296, Application Classification: Labeling
Submission status for HERON THERAPS INC's drug ZYNRELEF KIT (SUPPL-13) with active ingredient BUPIVACAINE; MELOXICAM has changed to 'Approval' on 01/23/2024. Application Category: NDA, Application Number: 211988, Application Classification: Efficacy
S-8 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
10-Q - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
8-K - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Filer)
SC 13D/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)
SC 13G/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)
SC 13G/A - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Subject)
-The U.S. Food and Drug Administration ("FDA") assigned a Prescription Drug User Fee Act ("PDUFA") goal date of September 23, 2024SAN DIEGO, July 2, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the FDA acknowledged the receipt of the Company's Prior Approval Supplement ("PAS") application for ZYNRELEF® (bupivacaine and meloxicam) extended-release solution VAN. The FDA has assigned a PDUFA goal date of September 23, 2024.If approved, the introduction of the VAN will replace the current vented vial spike and has the potential to simplify aseptic preparation, while also significantly reduci
SAN DIEGO, Sept. 3, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Brett Fleshman as Chief Business Officer. Mr. Fleshman will contribute his 25 years of experience in corporate and business development, commercial strategy, and marketing of pharmaceuticals, biologics, and surgical devices to the management team enabling the next phase of growth. "Now is the right time to add substantial BD and M&A experience to the management team at Heron, and I welcome Brett to
SAN DIEGO, June 23, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, announced today the appointment of Ira Duarte as Chief Financial Officer. Ms. Duarte has more than twenty-five years of experience in a variety of finance and accounting positions, including over a decade in the pharma industry. "I am excited to welcome Ira to Heron as Chief Financial Officer," said Craig Collard, Chief Executive Officer of Heron. "I had the pleasure of previously working with Ira and I look forward to her contribut
SAN DIEGO, June 12, 2023 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the appointment of William Forbes, Pharm.D., as Executive Vice President, Chief Development Officer. In addition, Kimberly Manhard, Heron's Executive Vice President, Drug Development, has resigned from her position. Dr. Forbes joins Heron's management team and will be responsible for leading clinical and product development for Heron's acute care and oncology care franchises. "I am thrilled to welcome Bill to the He
Second quarter Net Product Sales of $36.0 million, which increased from $31.8 million for the same period in 2023ZYNRELEF® Vial Access Needle ("VAN") PDUFA goal date set for September 23, 2024ZYNRELEF included in the proposed 2025 Non-Opioid Policy for Pain Relief ("NOPAIN Act")SAN DIEGO, Aug. 6, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced financial results for the three and six months ended June 30, 2024, and highlighted recent corporate updates. "We have had an exciting start to 2024 with many encouraging milestones that provide the foundation for ongoing commercial success. We are improvi
SAN DIEGO, July 30, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, August 6, 2024, at 4:30 p.m. ET to report second quarter 2024 financial results and discuss recent business highlights. The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator with the passcode 1737564 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at www.herontx.com. An archive of the teleconference and webcast
Net Product Sales of $34.7 million, which increased from $29.6 million for the same period in 2023. Net Loss Per Share $(0.02), which decreased from $(0.27) for the same period in 2023.Launched partnership with CrossLink Life Sciences, LLC to expand ZYNRELEF® promotional efforts in the first quarter of 2024.Gross Margin improved to 76% for the quarter, up from 43% for the same period last year.FDA approval of expanded indication for ZYNRELEF received on January 23, 2024.Heron to host its first ever Investor Day event on Wednesday, May 15, 2024 in New York, New York.SAN DIEGO, May 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage bio
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)
4 - HERON THERAPEUTICS, INC. /DE/ (0000818033) (Issuer)